Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03832998 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 284
- Enrollment target
NCT03832998 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 284 participants.
The verdict
NCT03832998, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 284 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with chronic migraine. The study hypothesis is that in pediatric participants with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Interventions
- OTHER Placebo
- DRUG Erenumab Dose 1
- DRUG Erenumab Dose 2
- DRUG Erenumab Dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2026-01-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03832998
The ClinicalTrials.gov registry entry for NCT03832998 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 284 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03832998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03832998 about?
NCT03832998 is a clinical study titled "Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine". This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with chronic migraine. The study hypothesis is that in pediatric participants with chronic migraine, the combined erenumab dose group has a greater red...
What is the current status of trial NCT03832998?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 284 participants. The study started on 2019-09-05. Estimated completion is 2026-01-07.
What interventions are being tested in trial NCT03832998?
The interventions under investigation include: Placebo (OTHER), Erenumab Dose 1 (DRUG), Erenumab Dose 2 (DRUG), Erenumab Dose 3 (DRUG).
Who is sponsoring clinical trial NCT03832998?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.